ArticleJournal of virology2005
Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Single-cell and spatial transcriptome-based metabolism-immunity interaction network and therapeutic target discovery of matrine in cervical cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Non-human primate papillomavirus E6-mediated p53 degradation reveals ancient evolutionary adaptation of carcinogenic phenotype to host niche.PLoS pathogens · 2022Article
- Review
- HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53.Cell death and differentiation · 2020Article
- HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3.International journal of molecular sciences · 2020Article
- Delineation of the HPV11E6 and HPV18E6 Pathways in Initiating Cellular Transformation.Frontiers in oncology · 2017Article
- Inhibition of antiviral drug cidofovir on proliferation of human papillomavirus-infected cervical cancer cells.Experimental and therapeutic medicine · 2016Article
- Papillomavirus E6 oncoproteins.Virology · 2013Review
- The CRM1 nuclear export protein in normal development and disease.International journal of biochemistry and molecular biology · 2012Article
- p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.Journal of virology · 2012Article
- Sts1 plays a key role in targeting proteasomes to the nucleus.The Journal of biological chemistry · 2011Article
- p53-based cancer therapy.Cold Spring Harbor perspectives in biology · 2010Review
- Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.The Journal of biological chemistry · 2009Article
- The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.International journal of cancer · 2009Article
- Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses.Virology journal · 2008Article
- Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.Oncogene · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The E6 protein from high-risk human papillomaviruses (HPVs) targets the p53 tumor suppressor for degradation by the proteasome pathway. This ability contributes to the oncogenic potential of these viruses. However, several aspects concerning the mechanism of E6-mediated p53 degradation at the cellular level remain to be clarified. This study therefore examined the role of cell localization and ubiquitination in the E6-mediated degradation of p53. As demonstrated within, following coexpression both p53 and high-risk HPV type 18 (HPV-18) E6 (18E6) shuttle from the nucleus to the cytoplasm. Mutation of the C-terminal nuclear export signal (NES) of p53 or treatment with leptomycin B inhibited the 18E6-mediated nuclear export of p53. Impairment of nuclear export resulted in only a partial reduction in 18E6-mediated degradation, suggesting that both nuclear and cytoplasmic proteasomes can target p53 for degradation. This was also consistent with the observation that 18E6 mediated the accumulation of polyubiquitinated p53 in the nucleus. In comparison, a p53 isoform that localizes predominantly to the cytoplasm was not targeted for degradation by 18E6 in vivo but could be degraded in vitro, arguing that nuclear p53 is the target for E6-mediated degradation. This study supports a model in which (i) E6 mediates the accumulation of polyubiquitinated p53 in the nucleus, (ii) E6 is coexported with p53 from the nucleus to the cytoplasm via a CRM1 nuclear export mechanism involving the C-terminal NES of p53, and (iii) E6-mediated p53 degradation can be mediated by both nuclear and cytoplasmic proteasomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.